MoonLake Immunotherapeutics (MLTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, MoonLake Immunotherapeutics (MLTX) has a cash flow conversion efficiency ratio of -0.193x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-58.79 Million) by net assets ($304.48 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
MoonLake Immunotherapeutics - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how MoonLake Immunotherapeutics's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of MoonLake Immunotherapeutics for a breakdown of total debt and financial obligations.
MoonLake Immunotherapeutics Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MoonLake Immunotherapeutics ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Superior Plus Corp
TO:SPB
|
0.408x |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771
|
0.067x |
|
IDT Corporation
NYSE:IDT
|
-0.029x |
|
Shaanxi Heimao Coking Co Ltd
SHG:601015
|
0.086x |
|
UOA Development Bhd
KLSE:5200
|
0.005x |
|
EcoRodovias Infraestrutura e Logística S.A
SA:ECOR3
|
0.312x |
|
Gold.com, Inc.
NASDAQ:GOLD
|
-0.098x |
|
MBB INDUSTRIES
XETRA:MBB
|
0.067x |
Annual Cash Flow Conversion Efficiency for MoonLake Immunotherapeutics (2020–2025)
The table below shows the annual cash flow conversion efficiency of MoonLake Immunotherapeutics from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see MLTX market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $304.48 Million | $-196.01 Million | -0.644x | -150.34% |
| 2024-12-31 | $453.39 Million | $-116.59 Million | -0.257x | -208.67% |
| 2023-12-31 | $513.49 Million | $-42.78 Million | -0.083x | +89.75% |
| 2022-12-31 | $68.77 Million | $-55.89 Million | -0.813x | -126.91% |
| 2021-12-31 | $-11.65 Million | $-35.18 Million | 3.021x | +107387.54% |
| 2020-12-31 | $112.48 Million | $-316.69K | -0.003x | -- |
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplan… Read more